- Pluri has completed the first phase of a contract development and manufacturing programme with Resbiomed, focused on process development and feasibility for placenta-derived biomaterials.
- The collaboration will now move into a second phase covering process definition, reproducibility and manufacturing readiness
Pluri, Inc. has completed the first phase of its programme with Resbiomed Technologies OOD, a European biotechnology company developing extracellular-matrix-based biomaterials and biologics for regenerative medicine. The work is being carried out through Pluri’s contract development and manufacturing division, PluriCDMO™.
The collaboration began in June 2025, when Pluri Biotech Ltd., a wholly owned subsidiary of the company, entered into an agreement with Resbiomed to apply Pluri’s placenta-derived processing and bioprocessing capabilities to support scalable production of placenta-derived biomaterials containing naturally occurring human collagen. The first phase focused on initial process development and feasibility.
Following completion of this phase, the parties plan to move forward to a next stage aimed at further process definition, reproducibility and manufacturing readiness. Progression is subject to mutually agreed scope, timelines and applicable requirements.
Under the programme, Pluri is supporting the establishment of protocols for tissue extraction, separation and processing designed to preserve and enhance endogenous collagen components. The collaboration combines Pluri’s experience in placenta-derived manufacturing with Resbiomed’s focus on extracellular-matrix biomaterials.
“We are pleased to announce the completion of the first phase of our program with Resbiomed. Resbiomed has built an impressive focus and expertise in ECM-based biomaterials, and we value the strength of the collaboration.”
Yaky Yanay, Chief Executive Officer and President of Pluri
